Modality
Gene Therapy
MOA
BETi
Target
WEE1
Pathway
Cell Cycle
Narcolepsy
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Feb 2029
NDA/BLACurrent
NCT04725157
697 pts·Narcolepsy
2022-03→2029-02·Active
697 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-022.8y awayPh3 Readout· Narcolepsy
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
NDA/BLA
Active
Catalysts
Ph3 Readout
2029-02-02 · 2.8y away
Narcolepsy
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04725157 | NDA/BLA | Narcolepsy | Active | 697 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |